Creative Commons source reading · Headache and migraine
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Antonio Russo; Marcello Silvestro; Fabrizio Scotto di Clemente; Francesca Trojsi; Alvino Bisecco; Simona Bonavita; Alessandro Tessitore; Gioacchino Tedeschi
Originally published in The journal of headache and pain · 2020-06-09
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background erenumab was safe and effective in clinical trials for the prevention of migraine. However, real-life data are still lacking. Here we report the clinical experience from an Italian real-world setting using erenumab in patients with chronic migraine experiencing previous unsuccessful preventive treatments. Methods Seventy patients with chronic migraine and failure to ≥4 migraine preventive medication classes initially received monthly erenumab 70 mg s.c. Patients without a clinically meaningful improvement, considered as a > 30% reduction in headache days per month, after ≥3 months of therapy switched to monthly erenumab 140 mg. At the first administration and after 3 and 6 months, patients underwent extensive interviews to assess clinical parameters of disease severity and migraine-related disability and impact, and validated questionnaires to explore depression/anxiety, sleep, and quality of life (QoL). Finally, the Pain Catastrophizing Scale, Allodynia Symptom Checklist-12 and MIGraine attacks-Subjective COGnitive impairments scale (MIG-SCOG) were administered.
Discussion
Chronic migraine imposes a considerable negative burden that affects many important aspects of life, including marital, parenting, romantic and family relationships, career/financial achievement and stability, and overall health [40], and is recognized as the second-highest cause of years lived with disability, and the first in patients aged between 15 and 49 years [41].
Conclusion
Our data from the Italian real-world setting support monthly erenumab 70 or 140 mg s.c. as an effective preventive treatment able to reduce headache frequency and severity in a significant percentage of chronic migraine patients experiencing previous unsuccessful preventive treatments. In addition, erenumab showed a significant effect on migraine-related disability and migraine impact on daily living, as well as on both depressive and anxiety symptoms, health-related quality of life, quality of sleep and pain catastrophizing.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
